Authors

Peter Voorhees, MD, UNC School of Medicine at Chapel Hill

Latest:

Dr. Yu Discusses Observation Versus Treatment in Men with Prostate Cancer

Peter Yu, MD, director, Palo Alto Medical Foundation, president-elect, ASCO, discusses results of a review that examined men's treatment decisions after seeing a raise in their PSA levels.

Petros Grivas, MD

Latest:

Dr Grivas on Addressing Unmet Needs in Urothelial Cancer

Petros Grivas, MD, PhD, discusses several unmet needs within urothelial cancer, as well as how to potentially ameliorate them.

Petros Grivas MD, PhD

Latest:

ARPI-Based Combination Regimens – CONTACT-02 (Cabozantinib plus atezolizumab)

Panelists discuss how the CONTACT-02 trial highlights the potential of cabozantinib combined with atezolizumab in improving treatment outcomes for patients with advanced cancer.

Phat Le, MD

Latest:

Dr. Le on Research Needed to Address Unmet Needs in mCRC

Phat Le, MD, discusses research efforts that are needed to address unmet needs in metastatic colorectal cancer.

Phil Febbo, MD

Latest:

Dr. Febbo on the Impact of Oncotype DX Genetic Prostate Score

Phil Febbo, MD, chief medical officer, Genomic Health, discusses the impact the Oncotype DX Genetic Prostate Score (GPS) has on patients with clinically low-risk prostate cancer.

Philip A. Philip, MD, Karmanos Cancer Center

Philip A. Philip, MD, PhD, FRCP

Latest:

Dr. Philip on Adverse Events With Lutathera in NETs

Philip A. Philip, MD, PhD, FRCP, professor of medicine, Wayne State University School of Medicine, clinical professor of oncology at Barbara Ann Karmanos Cancer Institute, discusses adverse events (AEs) associated with Lutathera (lutetium Lu 177 dotatate) in neuroendocrine tumors (NETs).

Philip A. Philip, MD, PhD, FRCP, Karmanos

Philip A. Philip, MD, PhD, FRCP, Wayne State University

Philip Agop Philip, MD, PhD, FRCP, Barbara Ann Karmanos Cancer Institute

Philip B. Paty, MD

Latest:

Dr. Paty on High-Risk Period for Rectal Tumor Regrowth

Philip B. Paty, MD, surgeon, Memorial Sloan Kettering Cancer Center, discusses the high-risk period for rectal tumor regrowth in patients.

Philip Bierman, MD

Latest:

Dr. Bierman on Unmet Needs for Patients With CNS Involvement in Aggressive NHL

Philip Bierman, MD, professor, Internal Medicine, Division of Oncology & Hematology, University of Nebraska Medical Center, discusses unmet needs for patients with central nervous system (CNS) involvement in aggressive subtypes of non–Hodgkin lymphoma (NHL).

Philip C. Mack, PhD, UC Davis Cancer center

Philip D. Bonomi, MD

Latest:

Dr. Bonomi Discusses PD-L1 as a Biomarker in NSCLC

Philip D. Bonomi, MD, The Alice Pirie Wirtz Professor of Medical Oncology, Rush Medical College, medical oncologist, Rush University Medical Center, discusses PD-L1 as a biomarker in non-small cell lung cancer.

Philip D. Hansten, PharmD

Latest:

Drug Interactions With Tyrosine Kinase Inhibitors

Tyrosine Kinase Inhibitors (TKIs) are indicated for the treatment of a variety of malignancies, due to their ability to interfere with cell communication and growth. This review focuses on interactions that affect TKI metabolism.

Philip Friedlander, MD, PhD

Latest:

Combination BRAF-MEK Inhibition With Dabrafenib and Trametinib for BRAF-Mutant Melanoma

It is estimated that in 2014 more than 76,000 people will be diagnosed with melanoma and approximately 9700 people will die from the malignancy.

Philip J. Buffington, MD

Latest:

Dr. Buffington on MRI Fusion for Prostate Cancer

Philip J. Buffington, MD, chief medical officer, The Urology Group, discusses MRI fusion-guided biopsy in patients with prostate cancer.

Philip Kantoff, MD

Latest:

Chemotherapy is Indicated, Yet Used Infrequently, in Patients With MIBC

A review by AndrÃ© P. Fay, MD, on the data supporting the standard use of neoadjuvant and adjuvant chemotherapy for patients with muscle invasive bladder cancers.

Philip L. McCarthy, MD

Latest:

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.